POMEZIA, Italy, September 28, 2017 /PRNewswire/ --
The meeting was organized with the patronage of the University of Turin and dedicated to the memory of Prof. Ruggero Ceppellini, one of the most important Italian geneticist and immunologist of the 20th century. The meeting was focused on two of the most interesting molecules involved in hematological malignancies: CD38 and CD157, and attracted distinguished scientists and physicians from all over the world.
(Logo: http://mma.prnewswire.com/media/520214/Menarini_Ricerche_Logo.jpg )
Menarini Ricerche was invited to present an update on MEN1112, a humanized monoclonal antibody targeting CD157, which is co-developed with Oxford BioTherapeutics for the treatment of acute myeloid leukemia (AML), a disease with a poor outcome and a high unmet medical need for innovative therapies.
CD157, the target of MEN1112, is expressed on the leukemic blasts in almost 100% of the AML patients, providing a strong rationale for this therapeutic approach. In addition, the MEN1112 antibody is engineered to enhance its cytotoxic activity against CD157-positive tumor blasts.
MEN1112 is currently in early clinical development, and the ARMY study, a first in human study in patients with relapsed or refractory AML, is ongoing.
About the Menarini Group Menarini Group is an Italian pharmaceutical company, 12th in Europe out of 5,255 companies, and 36th company in the world out of 20,862 companies, with a turnover of more than 3.5 billion Euro and more than 16,700 employees. The Menarini Group has always pursued two strategic objectives: research and internationalization, and has a strong commitment to oncology research and development. As part of such commitment to oncology, Menarini is developing four investigational new oncological drugs. Two of them are biologics, namely the anti-CD157 antibody MEN 1112, and the toxin-conjugated, anti-CD205 antibody MEN 1309. In addition, Menarini has recently added two small molecules to its oncology pipeline, the dual PIM and FLT3 kinase inhibitor MEN 1703, and the PI3K inhibitor MEN 1611, in clinical development for the treatment of a variety of hematological and/or solid tumors. Menarini is active commercially in the most important therapeutic areas with products for cardiology, gastroenterology, pneumology, infectious diseases, diabetology, inflammation, and analgesia.
For further information please visit http://www.menarini.com
CONTACT: Annamaria Coscarella Ph.D. Tel: +390691184437, e-mail: firstname.lastname@example.org